Naltrexone vs. nefazodone for treatment of alcohol dependence: A placebo-controlled trial

Neuropsychopharmacology

Volumn 22, Issue 5, 2000, Pages 493-503

  Kranzler, Henry R ^a   Modesto Lowe, Vania ^a   Van Kirk, Jeffrey ^a  

^a Department of Psychiatry   (United States)

Author keywords

Alcohol dependence; Alcohol treatment; Alcoholism; Naltrexone; Nefazodone; Randomized control trial

Indexed keywords

NALTREXONE; NEFAZODONE; PLACEBO;

ADULT; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRINKING BEHAVIOR; DROWSINESS; DRUG EFFICACY; DRUG TOLERANCE; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MUSCLE WEAKNESS; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; SYMPTOMATOLOGY; VISUAL IMPAIRMENT; XEROSTOMIA;

ADULT; ALCOHOLISM; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; PATIENT COMPLIANCE; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TRIAZOLES;

EID: 0034057478     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00135-9     Document Type: Article

References (53)

1. Aguirre J.C., Del Arbol J.L., Raya J., Ruiz-Requena M.E., Irles J.R. Plasma beta-endorphin levels in chronic alcoholics. Alcohol. 7:1990;409-412.
2. Diagnostic and Statistical Manual of Mental Disorders. 3rd Ed. rev:1987;American Psychiatric Press, Washington DC.
3. Anton R.F., Moak D.H., Latham P.K. The obsessive compulsive drinking scale. A self-rated instrument for the quantification of thoughts about alcohol and drinking behavior Alcohol Clin Exp Res. 1:1995;92-99.
4. Banki C. Factors influencing monoamine metabolites and tryptophan in patients with alcohol dependence. J Neural Trans. 50:1981;98-101.
5. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch Gen Psychiat. 4:1961;461-471.
6. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd Ed:1988;Lawrence Erlbaum Associates, Hillsdale NJ.
7. Croop R.S., Faulkner E.B., Labriola D.F. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiat. 54:1997;1130-1135.
8. Crowley T.J., Wagner J.E., Zerbe G., Macdonald M. Naltrexone-induced dysphoria in former opioid addicts. Am J Psychiat. 142:1985;1081-1084.
9. Davidson D., Palfai T., Bird C., Swift R. Effects of naltrxone on alcohol self-adminstration in heavy drinkers. Alcohol Clin Exp Res. 23:1999;195-203.
10. Del Boca F.K., Kranzler H.R., Brown J., Korner P. Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin Exp Res. 20:1996;1412-1417.
11. Gehan E.A. A generalized Wilcoxon test for comparing arbitrarily singly censored samples. Biometrika. 52:1965;203-223.
12. Genazzani A., Nappi G., Facchinetti F., Mazzella G.L., Parrini D., Sinforiani E., Petaraglia F., Savoldi F. Central deficiency of beta-endorphin in alcohol addicts. J Clin Endocrinol Metab. 55:1981;583-586.
13. Gerra G., Caccavari R., Delsignore R., Bocchi R., Fertonani G., Passeri M. Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and nonfamilial alcohol patients. Curr Therapeut Res. 52:1992;291-295.
14. Gianoulakis C., Beliveau D., Angelogianni P., Meaney M., Thavundayil J., Tawar V., Duams M. Different pituitary beta-endorphin and adrenal cortisol response to ethanol in individuals with high and low risk for future development of alcoholism. Life Sci. 45:1989;1097-1109.
15. Gianoulakis C., Krishnan B., Thavundayil J. Enhanced sensitivity of pituitary β-endorphin to ethanol in subjects at high risk of alcoholism. Arch Gen Psychiat. 53:1996;250-257.
16. Gorelick DA (1989): Serotonin uptake blockers and the treatment of alcoholism. In Galanter M (ed), Recent Developments in Alcoholism, Vol. 7.
17. Gorelick D.A., Paredes A. Effect of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res. 16:1992;261-265.
18. Hersh D., Van Kirk J.R., Kranzler H.R. Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology. 139:1998;44-52.
19. Hesselbrock M., Babor T.F., Hesselbrock V., Meyer R.E., Workman K. Never believe an alcoholic? On the validity of self-report measures of alcohol dependence and related constructs. Int J Addict. 18:1983;593-609.
20. Johnson P.O., Neyman J. Tests of certain linear hypotheses and their application to some educational problems. Statist Res Memoirs. 1:1936;57-93.
21. Kabel D.I., Petty F. A double blind study of fluoxetine in severe alcohol dependence. Adjunctive therapy during and after inpatient treatment Alcohol Clin Exp Res. 20:1996;780-784.
22. Kranzler H.R., Burleson J.A., Korner P., Del Boca F.K., Bohn M.J., Brown J., Liebowitz N. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiat. 152:1995;391-397.
23. Kranzler H.R., Del Boca F., Korner P., Brown J. Adverse effects limit the usefulness of fluvoxamine for the treatment of alcoholism. J Subst Abuse Treat. 10:1993;283-287.
24. Kranzler H.R., Jaffe J.H. Medications for use in alcoholism rehabilitation. Graham A.W., Schultz T.K. Principles of Addiction Medicine. 2nd ed:1998;501-516 American Society of Addiction Medicine, Chevy Chase, MD.
25. Kranzler H.R., Modesto-Lowe V., Nuwayser E.S. A sustained-release naltrexone preparation for treatment of alcohol dependence. Alcohol Clin Exp Res. 22:1998;1074-1079.
26. Levine J., Schooler N.R. Saftee. A technique for the systematic assessment of side effects in clinical trials Psychopharmacol Bull. 22:1986;343-381.
27. Litten R.Z., Allen J. Advances in development of medications for alcoholism treatment. Psychopharmacology. 139:1998;20-33.
28. Mason B.J., Salvato F.R., Williams L.D., Ritvo E.C., Cutler R.B. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiat. 56:1999;719-724.
29. McCrady B.S., Dean L., DuBreuil E., Swanson S. The problem drinkers project. A programmatic application of social learning-based treatment Marlatt G.A., Gordon J.R. Relapse Prevention. Maintenance Strategies in the Treatment of Addictive Behaviors:1985;417-471 Guilford Press, New York.
30. Meert T.F., Awouters F., Niemegeers C.J.E., Schellekens K.H.L., Janssen P.A.J. Ritanserin reduces abuse of alcohol, cocaine, and fentanyl in rats. Pharmacopsychiatry. 24:1991;159-163.
31. Mendelson J.H., Ellingboe J., Keuhnle J.C., Mello N.K. Effects of naltrexone on mood and neuroendocrine function in normal adult males. Psychoneuroendocrinology. 3:1979;231-236.
32. Monti P.M., Abrams D.B., Binkoff J.A., Zwick W.R. Interpersonal skills and substance abuse. Theoretical and practical considerations Hollin C.R., Trower P. Handbook of Social Skills Training. Clinical Applications and New Directions:1986;Pergamon, New York.
33. Myers R.D., Lankford M., Bjork A. 5-HT2 receptor blockade by amperozide suppresses ethanol drinking in genetically preferring rats. Pharmacol Biochem Behav. 45:1993;741-747.
34. Naranjo C.A., Kadlec K.E., Sanhueza P., Woodley-Remus D., Sellers E.M. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther. 47:1990;490-498.
35. Naranjo C.A., Poulos C.X., Bremner K.E., Lanctot K.L. Fluoxetine attenuates alcohol intake and desire to drink. Int Clin Psychopharmacol. 9:1994;163-172.
36. Naranjo C.A., Sellers E.M., Roach C.A., Woodley D.V., Sanchez-Craig M., Sykora K. Zimelidine-induced variations in alcohol intake by nondepressed heavy drinkers. Clin Pharmacol Ther. 35:1984;374-381.
37. Naranjo C.A., Sellers E.M., Sullivan J.T., Woodley D.V., Kadlec K., Sykora K. The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther. 41:1987;266-274.
38. Naranjo C.A., Sullivan J.T., Kadlec K.E., Woodley-Remus D.V., Kennedy G., Sellers E.M. Differential effects of viqualine on alcohol intake and other consummatory behaviors. Clin Pharmacol Ther. 46:1989;301-309.
39. Olausson P., Ericson M., Petersson A., Kosowski A., Soderpalm B., Engel J.A. Nefazodone attenuates the behavioral and neurochemical effects of ethanol. Alcohol. 15:1998;77-86.
40. O'Malley S.S., Jaffe A.J., Chang G., Schottenfeld R.S., Meyer R.E., Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study Arch Gen Psychiat. 49:1992;894-898.
41. O'Malley S.S., Krishnan-Sarin S., Farren C., O'Connor P.G. Naltrexone- induced nausea in patients treated for alcohol dependence. Clinical predictors and evidence for opioid mediated effects J Clin Psychopharmacol. in press:2000.
42. Oslin D., Liberto J.G., O'Brien J., Krois S., Norbeck J. Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiat. 5:1997;324-332.
43. Roy A., Virkkunen M., Linnoila M. Serotonin in suicide, violence, and alcoholism. Coccaro E.F., Murphy D.L. Serotonin in Major Psychiatric Disorders. 1990;DC: American Psychiatric Press, Washington.
44. Roy-Byrne P., Pages K.P., Russo J.E., Blume A.W., Jaffe C., Kingsley E., Cowley D.S., Ries R.K. A double-blind placebo-controlled trial of nefazodone in the treatment of major depression in alcohol dependent patients. J Clin Psychopharmacol. in press:2000.
45. Selzer M.L. The Michigan Alcoholism Screening Test. The quest for a new diagnostic instrument Am J Psychiat. 127:1971;1653-1658.
46. Sobell L.C., Maisto S.A., Sobell M.B., Cooper A.M. Reliability of alcohol abusers' self-reports of drinking behavior. Behav Res Ther. 17:1979;157-160.
47. Sobell M.B., Maisto S.A., Sobell L.C., Cooper A.M., Cooper T.C., Sanders B. Developing a prototype for evaluating alcohol treatment effectiveness. Sobell L.C., Sobell M.B., Ward E. Evaluating Alcohol and Drug Abuse Treatment Effectiveness. Recent Advances:1980;Pergamon Press, New York.
48. Sobell MB, Sobell LC, Klajner F, Pavan D, Basian E (1986): The reliability of a timeline method for assessing normal drinker college students' recent drinking history: Utility for alcoholic research addict behav 11:149-161.
49. Spitzer R.L., Williams J.B.W., Gibbon M., First M.B. The Structured Clinical Interview for DSM-III-R. I. History, rationale, and description. Arch Gen Psychiat. 49:1992;624-629.
50. Swift R.M., Whelihan W., Kuznetsov O., Buongiorno G., Hsuing H. Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiat. 151:1994;1463-1467.
51. Taylor D.P., Carter R.B., Eison A.S., Mullins U.L., Smith H.L., Torrente J.R., Wright R.N., Yocca F.D. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiat. 56:1995;3-11.
52. Volpicelli J., Rhines K.C., Rhines J.S., Volpicelli L.A., Alterman A.I., O'Brien C.P. Naltrexone and alcohol dependence. Role of subject compliance Arch Gen Psychiat. 54:1997;737-742.
53. Volpicelli J.R., Alterman A.I., Hayashida M., O'Brien C. Naltrexone and the treatment of alcohol dependence. Arch Gen Psychiat. 49:1992;876-880.